Evidence map›Paper›PMID 32885898›Full record

ArticleThe oncologist2020

Professional Medical Writer Assistance in Oncology Clinical Trials.

Ramez Kouzy, Joseph Abi Jaoude, Walker Mainwaring, Timothy A Lin, Austin B Miller, Amit Jethanandani, Andres F Espinoza, Vivek Verma, Clifton D Fuller, Bruce D Minsky and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ramez Kouzy *The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-1521-0495
Joseph Abi Jaoude *The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Walker MainwaringBaylor College of Medicine, Houston, Texas, USA.
Timothy A LinThe Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Austin B MillerThe University of Texas Health Science Center McGovern Medical School, Houston, Texas, USA.
Amit JethanandaniThe University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee, USA.
Andres F EspinozaBaylor College of Medicine, Houston, Texas, USA.
Vivek VermaThe University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Clifton D FullerThe University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Bruce D MinskyThe University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Claus RödelUniversity of Frankfurt, Frankfurt, Germany.
Cullen M Taniguchi *The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ethan B Ludmir *The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MILLS, GORDON B. · 2002 to 2012
$26.1M
Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac deviceR01DE028290 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHRISTODOULEAS, JOHN PAUL, FULLER, CLIFTON DAVID · 2019 to 2023
$4.3M
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR01DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2016 to 2020
$2.9M
Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic CancerR01CA227517 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOONG, ALBERT · 2019 to 2023
$2.3M
SMART-ACT: Spatial Methodologic Approaches for Risk Assessment and Therapeutic Adaptation in Cancer TreatmentR01CA214825 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2017 to 2019
$1.1M
imaging Radiation-Associated Dysphagia (iRAD)R01CA218148 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FULLER, CLIFTON DAVID, HUTCHESON, KATHERINE ARNOLD · 2017 to 2019
$810k
Fellow and Resident Radiation Oncology iNtensive Training in Imaging and Informatics to Empower Research Careers (FRONTI2ER)R25EB025787 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAS, PRAJNAN, FULLER, CLIFTON DAVID · 2018 to 2022
$535k
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR56DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2015 to 2015
$470k
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA097007NCI NIH HHS R01 CA214825NCI NIH HHS R01 CA218148NCI NIH HHS R01 CA227517NIBIB NIH HHS R25 EB025787NIDCR NIH HHS R01 DE025248NIDCR NIH HHS R01 DE028290NIDCR NIH HHS R56 DE025248
6 · The paper itself

Abstract

backgroundThe use of professional medical writers (PMWs) has been historically low, but contemporary data regarding PMW usage are scarce. In this study, we sought to quantify PMW use in oncologic phase III randomized controlled trials (RCTs).

methodsWe performed a database query through ClinicalTrials.gov to identify cancer-specific phase III RCTs; we then identified whether a PMW was involved in writing the associated trial manuscript reporting primary endpoint results.

resultsTwo-hundred sixty trials of 600 (43.3%) used a PMW. Industry-funded trials used PMWs more often than nonindustry trials (54.9% vs. 3.0%, p < .001). Increased PMW usage was further noted among trials meeting their primary endpoint (53.4% vs. 32.9%, p < .001) and trials that led to subsequent Food and Drug Administration approval (63.1% vs. 36.3%, p < .001). By treatment interventions, PMW use was highest among systemic therapy trials (50.2%). Lastly, the use of PMWs increased significantly over time (odds ratio: 1.11/year, p = .001).

conclusionPMW use rates are high among industry-funded trials. We urge continued and increased transparency in reporting the funding and use of PMWs.

Indexed as

Medical WritingNeoplasmsHumansMedical OncologyOdds RatioRandomized Controlled Trials as Topic

Identifiers

PMID32885898
PMCPMC7648360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.